# Miromatrix Medical

its miroliverELAP, a bioengineered extracorporeal liver support device built from decellularized porcine liver matrix recellularized with human cells, received FDA RMAT (Regenerative Medicine Advanced Therapy) designation.

Source: https://en.bioecon.ru/companies/miromatrix-medical/
Updated: 2026-07-03

- Country: United States

## Verifiable facts

| Fact | Value | Source |
| --- | --- | --- |
| Funding | Acquired by United Therapeutics for approximately $91M-$140M in December 2023 | https://finance.yahoo.com/news/united-therapeutics-acquire-miromatrix-medical-100500482.html, https://ir.unither.com/press-releases/2023/12-13-2023-141512381 |
| Capacity | Over 1,000 bioengineered organs per year | https://www.sec.gov/Archives/edgar/data/1527096/000155837023005278/miro-20221231x10k.htm |
| Regulatory approval | FDA Regenerative Medicine Advanced Therapy (RMAT) designation; FDA Investigational New Drug (IND) clearance | https://ir.unither.com/press-releases/2026/04-08-2026-120021960, https://www.businesswire.com/news/home/20260408473035/en/United-Therapeutics-Receives-FDA-Regenerative-Medicine-Advanced-Therapy-Designation-for-miroliverELAP-for-Treatment-of-Acute-Liver-Failure, https://www.miromatrix.com/about-us |
| Production site | 11,000 square foot in-house manufacturing facility at corporate headquarters in Eden Prairie, Minnesota | https://www.sec.gov/Archives/edgar/data/1527096/000155837023005278/miro-20221231x10k.htm |
| Headcount | 76 full-time employees as of March 20, 2023 | https://www.sec.gov/Archives/edgar/data/1527096/000155837023005278/miro-20221231x10k.htm |
| Revenue | Recorded $953,470 in royalty revenue in 2022 | https://www.sec.gov/Archives/edgar/data/1527096/000155837023005278/miro-20221231x10k.htm |

Independent sources: businesswire.com, finance.yahoo.com, ir.unither.com, sec.gov

## Technologies

- [Xenotransplantation](https://en.bioecon.ru/technology/xenotransplantation/)